RhumbLine Advisers
NAVB

RhumbLine Advisers’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

RhumbLine Advisers’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-8,197
Closed -$155K – 3055
2016
Q1 		$155K Buy
8,197
+173
+2% +$3.33K ﹤0.01% 2811
2015
Q4 		$213K Buy
8,024
+626
+8% +$21.7K ﹤0.01% 2766
2015
Q3 		$337K Buy
7,398
+308
+4% +$11.6K ﹤0.01% 2466
2015
Q2 		$228K Sell
7,090
-473
-6% -$13.7K ﹤0.01% 2817
2015
Q1 		$240K Buy
7,563
+1,220
+19% +$41.3K ﹤0.01% 2736
2014
Q4 		$240K Buy
6,343
+339
+6% +$9.32K ﹤0.01% 2699
2014
Q3 		$159K Hold
6,004
– – ﹤0.01% 2836
2014
Q2 		$178K Buy
6,004
+702
+13% +$22.7K ﹤0.01% 2875
2014
Q1 		$196K Sell
5,302
-279
-5% -$10.6K ﹤0.01% 2780
2013
Q4 		$231K Sell
5,581
-120
-2% -$4.7K ﹤0.01% 2741
2013
Q3 		$302K Sell
5,701
-34
-0.6% -$1.98K ﹤0.01% 2521
2013
Q2 		$306K Buy
+5,735
New +$286K ﹤0.01% 2625

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RhumbLine Advisers's NAVB Position: Q2 2016 in Review

RhumbLine Advisers sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 8,197 shares — an estimated $155K sold.

RhumbLine Advisers first reported a position in NAVB in Q2 2013 and held it in 12 quarters. The position peaked at $337K in Q3 2015. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

  • RhumbLine Advisers reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
  • RhumbLine Advisers sold 8,197 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $155K.
  • RhumbLine Advisers first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 12 quarters.
  • RhumbLine Advisers's Navidea Biopharmaceuticals Inc. position peaked at $337K in Q3 2015.
  • 63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on RhumbLine Advisers's 13F filing for Q2 2016, filed 11 Aug 2016.